Khosla Ventures Backs Scipher Medicine To Bring Precision Medicine To Autoimmune Diseases

Scipher Medicine (Scipher) recently completed a round of Series A funding led by venture capital firm Khosla Ventures. With the new funds it received, Scipher has raised a total of $10 million to date.

With the new funding, Scipher hopes to strengthen its molecular technology platform, which helps to predict how well consumers will respond to particular drugs. This service is very valuable, as 65% of people prescribed with the world top 5 highest selling drugs do not respond well to them. This fact not only threatens the health of consumers, but it is also one of the primary reasons . . .